16,562 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. purchased a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,562 shares of the biopharmaceutical company’s stock, valued at approximately $255,000.

Other large investors have also recently made changes to their positions in the company. M&G Plc boosted its stake in shares of ACADIA Pharmaceuticals by 12.4% during the 2nd quarter. M&G Plc now owns 351,115 shares of the biopharmaceutical company’s stock worth $5,618,000 after purchasing an additional 38,790 shares during the period. Fred Alger Management LLC lifted its holdings in ACADIA Pharmaceuticals by 19.8% during the 2nd quarter. Fred Alger Management LLC now owns 2,704,439 shares of the biopharmaceutical company’s stock valued at $43,947,000 after buying an additional 446,875 shares in the last quarter. US Bancorp DE lifted its holdings in ACADIA Pharmaceuticals by 2,084.0% during the 3rd quarter. US Bancorp DE now owns 32,934 shares of the biopharmaceutical company’s stock valued at $507,000 after buying an additional 31,426 shares in the last quarter. Sei Investments Co. lifted its holdings in ACADIA Pharmaceuticals by 6.2% during the 1st quarter. Sei Investments Co. now owns 34,752 shares of the biopharmaceutical company’s stock valued at $642,000 after buying an additional 2,034 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new stake in ACADIA Pharmaceuticals during the 3rd quarter valued at about $483,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ACAD. Citigroup decreased their price objective on shares of ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Morgan Stanley lowered shares of ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $28.00 to $20.00 in a report on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Royal Bank of Canada decreased their price objective on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reduced their price target on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $25.56.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 10,259 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $172,453.79. Following the sale, the chief financial officer now owns 53,302 shares of the company’s stock, valued at approximately $896,006.62. The trade was a 16.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Brendan Teehan sold 10,329 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $173,630.49. Following the sale, the chief operating officer now directly owns 62,105 shares in the company, valued at approximately $1,043,985.05. This represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,661 shares of company stock valued at $414,551. Insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Stock Up 1.0 %

NASDAQ ACAD opened at $16.54 on Tuesday. The firm has a market cap of $2.75 billion, a PE ratio of 21.21 and a beta of 0.38. The company has a 50 day moving average price of $15.61 and a 200 day moving average price of $15.97. ACADIA Pharmaceuticals Inc. has a 52 week low of $14.15 and a 52 week high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.14 by $0.06. The firm had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. ACADIA Pharmaceuticals’s revenue was up 18.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.40) EPS. On average, equities research analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.72 earnings per share for the current fiscal year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.